1-7 of 7
T.R. Jeffry Evans
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial

Andrew X. Zhu, Yoon-Koo Kang, Olivier Rosmorduc, T.R. Jeffry Evans, Armando Santoro, Paul Ross, Edward Gane, Arndt Vogel, Michael Jeffers, Gerold Meinhardt, Carol E.A. Peña
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (19): 4870–4879.
https://doi.org/10.1158/1078-0432.CCR-15-2883
Published: 02 October 2016
View article titled, Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
Open the PDF for Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Igor Puzanov, Colin R. Lindsay, Laura Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, Rich Gedrich, Andrew Stephens, Emily Chan, T.R. Jeffry Evans
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (4): 701–711.
https://doi.org/10.1158/1078-0432.CCR-14-0303
Published: 16 February 2015
View article titled, A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

Balaji Venugopal, Richard Baird, Rebecca S. Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan W. Smit, Ann Forslund, Charles Phelps, John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4262–4272.
https://doi.org/10.1158/1078-0432.CCR-13-0312
Published: 31 July 2013
View article titled, A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma

Nigel B. Jamieson, Douglas C. Morran, Jennifer P. Morton, Asif Ali, Euan J. Dickson, C. Ross Carter, Owen J. Sansom, T.R. Jeffry Evans, Colin J. McKay, Karin A. Oien
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 534–545.
https://doi.org/10.1158/1078-0432.CCR-11-0679
Published: 16 January 2012
View article titled, MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Open the PDF for MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

Martijn P. Lolkema, Hendrik-Tobias Arkenau, Kevin Harrington, Patricia Roxburgh, Rosemary Morrison, Victoria Roulstone, Katie Twigger, Matt Coffey, Karl Mettinger, George Gill, T.R. Jeffry Evans, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 581–588.
https://doi.org/10.1158/1078-0432.CCR-10-2159
Published: 01 February 2011
View article titled, A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
Open the PDF for A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer in another window
Journal Articles

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

George D. Demetri, Patricia Lo Russo, Iain R.J. MacPherson, Ding Wang, Jeffrey A. Morgan, Valerie G. Brunton, Prashni Paliwal, Shruti Agrawal, Maurizio Voi, T.R. Jeffry Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6232–6240.
https://doi.org/10.1158/1078-0432.CCR-09-0224
Published: 30 September 2009
View article titled, Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

Nicola L. Steele, Jane A. Plumb, Laura Vidal, Jette Tjørnelund, Poul Knoblauch, Annie Rasmussen, Chean Eng Ooi, Peter Buhl-Jensen, Robert Brown, T.R. Jeffry Evans, Johann S. DeBono
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 804–810.
https://doi.org/10.1158/1078-0432.CCR-07-1786
Published: 01 February 2008
View article titled, A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
Open the PDF for A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors in another window